142 related articles for article (PubMed ID: 37028478)
1. Spectral Analysis Based on Hemodynamic Habitat Imaging Predicts Isocitrate Dehydrogenase Status and Prognosis in High-Grade Glioma.
Qiao J; Wu H; Liu J; Kang H; Wang S; Fang J; Zhang J; Zhang W
World Neurosurg; 2023 Jul; 175():e520-e530. PubMed ID: 37028478
[TBL] [Abstract][Full Text] [Related]
2. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
[TBL] [Abstract][Full Text] [Related]
3. Metabolic habitat imaging with hemodynamic heterogeneity predicts individual progression-free survival in high-grade glioma.
Qiao J; Kang H; Ran Q; Tong H; Ma Q; Wang S; Zhang W; Wu H
Clin Radiol; 2024 Jun; 79(6):e842-e853. PubMed ID: 38582632
[TBL] [Abstract][Full Text] [Related]
4. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas.
Liu J; Cong C; Zhang J; Qiao J; Guo H; Wu H; Sang Z; Kang H; Fang J; Zhang W
Clin Radiol; 2024 Jan; 79(1):e127-e136. PubMed ID: 37923627
[TBL] [Abstract][Full Text] [Related]
5. 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.
Cadrien C; Sharma S; Lazen P; Licandro R; Furtner J; Lipka A; Niess E; Hingerl L; Motyka S; Gruber S; Strasser B; Kiesel B; Mischkulnig M; Preusser M; Roetzer-Pejrimovsky T; Wöhrer A; Weber M; Dorfer C; Trattnig S; Rössler K; Bogner W; Widhalm G; Hangel G
Cancer Imaging; 2024 May; 24(1):67. PubMed ID: 38802883
[TBL] [Abstract][Full Text] [Related]
6. The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.
Goryawala M; Saraf-Lavi E; Nagornaya N; Heros D; Komotar R; Maudsley AA
J Neuroimaging; 2020 Jan; 30(1):58-64. PubMed ID: 31868291
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
[TBL] [Abstract][Full Text] [Related]
8. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
10. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
12. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
Guo D; Jiang B
Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
[TBL] [Abstract][Full Text] [Related]
13. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
14. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
15. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
16. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
17. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
18. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
20. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
